Equites Radar

RGEN · Repligen Corporation

Medical Instruments & SuppliesUnited StatesAnalyst view: Strong Buy

$165.85

+0.71% last session

End-of-day data · close of 2026-09-11

Mildly bullish3 bullish · 1 bearish technical signals
Consensus: Buy (1.50 from 21 analysts)
To mean target: +15.1%

Market cap

$9B

Enterprise value

$9B

Trailing P/E

225.6

Forward P/E

62.2

Dividend yield

Beta

1.05

Avg volume

1M

Employees

2K

Daily Change %

0.71%

5 Days Change

-1.52%

10 Days Change

-8.80%

30 Days Change

0.17%

60 Days Change

14.43%

Month to Day Change

-2.92%

Year to Day Change

0.73%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)1.50
Covering analysts21
Mean price target$189.48
Low price target$145.00
Upside to mean target+15.1%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)48.6
50-day MA$157.73
200-day MA$142.17
Price vs 50-day MA+5.2%
Price vs 200-day MA+16.7%
MACD histogram-2.63
Volume vs 3-month avg0.3×
52w low $102.8752w high $182.03

Analyst sentiment over time — RGEN

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-09-09

Latest call per bank · past 12 months

UBS

Buy

$225

+36.6% vs price
▲ raised from $195Maintains · 2026-09-09

Wells Fargo

Overweight

$185

+12.3% vs price
▲ raised from $180Maintains · 2026-07-30

JP Morgan

Overweight

$175

+6.3% vs price
▲ raised from $165Maintains · 2026-07-29

HSBC

Buy

$150

-8.9% vs price
▼ cut from $170Maintains · 2026-06-03

Barclays

Overweight

$160

-2.8% vs price
▲ raised from $145Maintains · 2026-05-06

Jefferies

Hold

$135

-18.0% vs price
▼ cut from $145Maintains · 2025-09-12

Recent rating actions

DateFirmActionRatingPrice target
2026-09-09UBSMaintainsBuy$195 $225
2026-07-30Wells FargoMaintainsOverweight$180 $185
2026-07-29JP MorganMaintainsOverweight$165 $175
2026-07-07BenchmarkUpgradeHoldBuy$0.00 $185
2026-07-06Evercore ISI GroupMaintainsOutperform$150 $160
2026-06-03HSBCMaintainsBuy$170 $150
2026-05-06JP MorganMaintainsOverweight$180 $165
2026-05-06BarclaysMaintainsOverweight$145 $160

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-09-11

  • RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 5.2% above the 50-day MA ($157.73).
  • Price vs 200-day MA: Trading 16.7% above the 200-day MA ($142.17).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-2.63) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($102.87) and high ($182.03).

RGEN Price Chart

Loading chart for RGEN

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$37.43
Net Debt / EBITDA-0.8
WACC11.0%
Revenue growth12.00%
Earnings growth-66.00%

About Repligen Corporation

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

More in Medical Instruments & Supplies

Screen RGEN against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.